

China-based 3D printing pharma startup secures funding worth \$50 M

25 June 2021 | News

The proceeds	will also be a	ised to expand	d the 3D prin	ited drug nr	nduct nineline
THE DIVECTOR	Will also be t	ioca to expain	u 1110 00 01 11	iteu ui uu bi v	Juuct Dibeillie

Triastek, Inc., the first 3D printing pharmaceutical company in China, has completed its Series B financing, raising \$ 50 million (RMB 330 million).

This round of investment was co-led by Matrix Partners China and CPE, with participation from Shanghai Sci-Tech Innovation Center Capital (SSICC) and existing investors, Morningside Ventures, Dalton Venture and Yungi Partners.

In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline and advancing Triastek's vision of creating a new era of global intelligent pharmaceutical manufacturing.

Triastek co-founder and CEO Dr. Senping Cheng said, "We appreciate the support from Matrix Partners China, CPE, SSICC and our existing shareholders. It is Triastek's unrelenting goal to develop cutting-edge therapeutics that address unmet patient needs, revolutionize pharmaceutical manufacturing and improve human health. We will leverage the advantages of 3D printing of pharmaceuticals as a digital manufacturing technology and incorporate emerging technologies such as artificial intelligence to lead off a new era in advanced, intelligent pharmaceutical manufacturing."